• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Patent office to review United Therapeutics, SteadyMed patent conflict

April 12, 2016 By Fink Densford

SteadyMed still steady on Q2SteadyMed Therapeutics (NASDAQ:STDY) said today it that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated an inter partes review against a United Therapeutics patent.

The patent in question, No. 8,497,393, is related to a process to purify prostacyclin derivatives, such as treprostinil, which is used in United Therapeutics’ Remodulin and SteadyMed’s drug candidate Trevyent, designed to treat pulmonary arterial hypertension.

“The initiation of this IPR by PTAB is a significant decision in favor of SteadyMed. While we have an appreciation for the patent process in the U.S., we believe that the patent in question is invalid. We are pleased that the PTAB, by its action to institute the formal review process, appears to believe that there is sufficient doubt about the validity of certain claims of the ‘393 patent. We look forward to submitting our new drug application for Trevyent, which has been granted orphan designation, later this year. We are eager to see patients benefit from Trevyent, if approved, we have begun early preparation work for commercialization and believe that we will make significant in-roads to the PAH market,” CEO Jonathan Rigby said in a press release.

San Ramon, Calif.-based Steadymed said that IPR reports from 2012-2015 indicated that 74% of reviews were resolved by finding all claims unpatentable, cancelling claims and rendering patents invalid. Only 14% of cases were resolved by finding some claims unpatentable and cancelling those, and 12% were resolved by finding all claims patentable.

Last July, SteadyMed said it inked an exclusive deal with Cardiome for commercialization of its Treyvant product in regions outside the U.S., hinging on its regulatory approval in those regions.

Cardiome will have exclusive rights to the territories of the European Union, Canada and the Middle East, SteadyMed said.

Filed Under: Drug-Device Combinations Tagged With: SteadyMed Therapeutics

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS